TYK Medicines, Inc
🇭🇰Hong Kong, China
Clinical Trials
16
Active:0
Completed:5
Trial Phases
4 Phases
Phase 1:10
Phase 2:3
Phase 3:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 1
10 (62.5%)Phase 2
3 (18.8%)Not Applicable
2 (12.5%)Phase 3
1 (6.3%)Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT07104643
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）
Not Applicable
Not yet recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- Drug: Abiraptor
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT07104617
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- HR-positive, HER2-negative Advanced Breast Cancer
- Interventions
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 180
- Registration Number
- NCT06950086
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC
Phase 2
Not yet recruiting
- Conditions
- NSCLC
- Interventions
- Drug: TY-9591 80mg QD+pemetrexed+Cisplatin/CarboplatinDrug: TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT06672068
Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT06255951
- Locations
- 🇨🇳
Yali Liu, Guangdong, Shantou, China
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found